As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Fulcrum is a publishing platform that helps publishers present the full richness of their authors.
News
After failure in sickle cell, Fulcrum merges with Slate
Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
Read more
Report
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Read more
Report
Slate, Fulcrum to combine in reverse merger
Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.
Read more
Report
Pro access
Upgrade to see all 37 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
